Malaria vaccine trial results 'promising'.Some much-anticipated results have come in from a major trial of a vaccine against malaria. Trials have been done with the RTS (Request To Send) An RS-232 signal sent from the transmitting station to the receiving station requesting permission to transmit. Contrast with CTS.
1. (operating system) RTS - run-time system.
2. , S vaccine, developed by GlaxoSmithKline (GSK GSK GlaxoSmithKline plc (pharmaceutical company)
GSK Glycogen Synthase Kinase
GSK Gruppentraining Sozialer Kompetenzen (Germany)
GSK Greenland Shark (FAO fish species code) ), in seven African countries. The first phase three results, published online in the New England Journal of Medicine The New England Journal of Medicine (New Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. , show that the vaccine cut the risk of malaria infection by about half. Normally, a vaccine that decreases cases of infection by half would be considered a failure. But the numbers affected by malaria are so high - it is one of the biggest killers of children in Africa - that the World Health Organization has said this vaccine trial is worth pursuing.
The philanthropist Bill Gates, who has given billions of dollars to fund vaccines in the developing world, was upbeat: 'It is very promising. The very fact that this vaccine works gives us data about how to build better vaccines and it gives us a tool to combine with bed-nets, spraying, mosquito killing - all these different interventions - that will help us bring the number of deaths down quite a bit.' The upbeat message about the results has to be tempered by a couple of factors.
Firstly, there were more side-effects in the group vaccinated against malaria than in the control group who received a rabies vaccine. For example, there were cases of meningitis and seizures. This will need to be monitored carefully. Secondly, there is some evidence that the effectiveness of the malaria vaccine might have waned over a year. Andrew Witty, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of GSK, said that the trial would continue to follow up thousands of children in the future. 'Over the next couple of years we will get a very clear view on what's really happening with protection. Is it waning or is it that people are acquiring their natural immunity. Do we need a booster dose or not? All that will become clear.' Bed nets and insecticides will remain vital in the fight against malaria - the vaccine is no magic bullet - but even a jab that was 50% effective could save huge numbers of lives in the years to come.